REGN RSI

What is REGN?

Regeneron Pharmaceuticals was founded in 1988 by Leonard Schleifer and George Yancopoulos with a mission to use the power of science to bring new medicines to patients repeatedly and consistently. Based in Tarrytown, New York, the company has grown from a small startup into a multi-billion-dollar biotechnology leader. Its business model is uniquely built around a science-first approach, powered by its proprietary VelociSuite technologies, which allow for the rapid development of fully human antibodies. This internal R&D engine is the heart of the company, reducing the time and cost typically associated with drug discovery.

The product portfolio is anchored by two massive blockbusters: Eylea, which treats various forms of vision loss, and Dupixent, a versatile drug co-developed with Sanofi used for asthma, eczema, and other inflammatory conditions. Beyond these, Regeneron is expanding into oncology with Libtayo and a promising pipeline of bispecific antibodies. Historically, the company hit its stride in 2011 with the approval of Eylea, and more recently, it gained global recognition for its rapid development of a monoclonal antibody cocktail during the COVID-19 pandemic.

Financially, Regeneron is in a very strong position. It maintains high profit margins and a robust balance sheet, allowing it to self-fund an aggressive R&D budget that often exceeds $4 billion annually. The company has successfully navigated patent cliffs by innovating higher-dose formulations of its existing products, effectively extending its market exclusivity and protecting its revenue streams.

Looking toward 2026, the strategic outlook is focused on diversification and lifecycle management. A major catalyst will be the expanded use of Dupixent in COPD, which could significantly increase its total addressable market. Additionally, the company expects its oncology division to become a primary growth driver as it seeks new indications for Libtayo and progresses its pipeline of genetics-based therapies. By leveraging the Regeneron Genetics Center, the firm aims to pioneer precision medicine, ensuring its long-term relevance in an increasingly competitive biotech landscape.

What is RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and magnitude of price changes. Developed by J. Welles Wilder, RSI ranges from 0 to 100 and helps traders identify overbought or oversold conditions in an asset.

For REGN, monitoring the RSI provides valuable insights into potential trend reversals and entry/exit points. When the RSI drops below 30, Regeneron Pharmaceuticals Inc is typically considered oversold, suggesting the asset may be undervalued. Conversely, an RSI above 70 indicates overbought conditions.

Understanding REGN RSI Signals

• Oversold (RSI below 30): When REGN RSI falls below 30, it suggests the asset may have been sold off excessively and could be due for a bounce. This is often viewed as a potential buying opportunity, though it's important to consider other factors and not rely solely on RSI.
• Overbought (RSI above 70): An RSI above 70 indicates REGN may be overbought, potentially signaling a pullback or consolidation phase. Traders often use this as a signal to take profits or wait for better entry points.
• Divergences: When REGN price makes new highs or lows but RSI doesn't confirm these moves, it can signal weakening momentum and a possible trend reversal.

Daily vs Weekly RSI for REGN

This page displays both daily and weekly RSI for REGN. The daily RSI responds quickly to short-term price movements, making it useful for day traders and swing traders. The weekly RSI provides a broader perspective on momentum trends, helping longer-term investors identify major oversold or overbought conditions.

By analyzing both timeframes together, you can better understand Regeneron Pharmaceuticals Inc's momentum at multiple levels and make more informed trading decisions.

Historical RSI Oversold Analysis

Above, we track historical instances when REGN RSI dropped below 30 (oversold territory). Reviewing these past oversold levels helps identify patterns and understand how Regeneron Pharmaceuticals Inc has historically responded to oversold conditions. Many traders use these historical reference points to gauge potential support levels and timing for entry positions.